Efficacy of duloxetine in painful symptoms: An analgesic or antidepressant effect?

International Clinical Psychopharmacology

Volumn 21, Issue 6, 2006, Pages 311-317

  Perahia, David G S ^a,b   Pritchett, Yili L ^a   Desaiah, Durisala ^a   Raskin, Joel ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Gordon Hospital   (United Kingdom)

Author keywords

Analgesic effects; Diabetic peripheral neuropathic pain; Duloxetine; Fibromyalgia; Major depressive disorder

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; DULOXETINE; PLACEBO;

CLINICAL TRIAL; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; FIBROMYALGIA; HUMAN; MAJOR DEPRESSION; NEUROPATHIC PAIN; PAIN; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE;

ANALGESICS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DEPRESSIVE DISORDER; DIABETIC NEUROPATHIES; FIBROMYALGIA; HUMANS; PAIN; THIOPHENES; TREATMENT OUTCOME;

EID: 33749315762     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224782.83287.3c     Document Type: Review

References (48)

1. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, District of Columbia: American Psychiatric Association.
2. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al.; Duloxetine Fibromyalgia Trial Group (2004). A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50:2974-2984.
3. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. (2005). A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5-15.
4. Boulton AJ, Gries FA, Jervell JA (1998). Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 15:508-514.
5. Brannan SK, Mallincrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF (2005). Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39:43-53.
6. Bymaster FP, Dreshfield-Ahmad LJ, Threkeld PG, Shaw JL, Thompson L, Nelson DL, et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880.
7. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, et al. (2002). Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 160:353-361.
8. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S (2005). The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 11:1475-1493.
9. Caballero L, Aragones E, Garcia-Campayo J, Rodriguez-Artaleio F, Ayuso-Mateos JL, Paolavieja MJ, et al. (2005). Results of a Spanish nationwide cross-sectional study on major depression in primary care I: prevalence and characteristics of somatic symptoms. Intl J Psychiatry Clin Pract 9:320.
10. Demyttenaere K, Bonnewyn A, Bruffaerts R, Brugha T, De Graaf R, Alonso J (2006). Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking. J Affect Disord 92:185-193.
11. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002a). Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.
12. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA (2002b). Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36:383-390.
13. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paraoxetine-controlled trial. Eur Neuropsychopharmacol 14:457-470.
14. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149-158.
15. Fava M (2002). Somatic Symptoms, depression, and antidepressant treatment. J Clin Psychiatry 63:305-307.
16. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM (2004). The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 65:521-530.
17. Fields HL, Basbaum AI (1994). Central nervous system mechanisms of pain modulation. In: Wall P, Melzack R, editors. Textbook of pain. New York: Churchill Livingstone. pp. 243-257.
18. Fishbain DA (1999). The association of chronic pain and suicide. Semin Clin Neuropsychiatry 4:221-227.
19. Goldstein DJ, Yili L, Detke M, Wiltse C, Mallinckrodt C, Demitrack MA (2002). Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Biol Psychiatry 51 (Suppl 1):123S.
20. Goldstein DJ, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack MA (2004a). Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24:389-399.
21. Goldstein DJ, Lu Y, Detke MJ, Hudson JI, Demitrack MA (2004b). Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45:17-28.
22. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (2005). Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116:109-118.
23. Greco T, Eckert G, Kroenke K (2004). The outcome of physical symptoms with treatment of depression. J Gen Intern Med 19:893-895.
24. Greden JF (2001). The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry 62 (Suppl 22):5-9.
25. Griffin RS, Woolf CJ (2005). The pathophysiologic basis of drug therapy. In: Golan DE, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS, editors. Principles of pharmacology. Lippincott Williams and Wilkins, Baltimore, MD; pp. 229-246.
26. Hirschfield RM (2000). History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 61 (Suppl 6):4-6.
27. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML (2005). Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 27:1126-1143.
28. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RMA (2004). Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311:576-584.
29. Johnson RA, Wichern DW (1992). Applied multivariate statistical analysis. 3rd ed. Prentice Hall, New Jersey.
30. Kasamo K, Blier P, De Montigny C, Debonnel G (1996). Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther 277:278-286.
31. Koch S, Perry KW, Nelson DL, Conway RG, Threkled PG, Bymaster FP (2002). R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis receptor and binding study. Neuropsychopharmacology 27:949-959.
32. Koch S, Hemrick-Lueck SK, Thomson LK, Evans DC, Threkeld PG, Nelson DL, et al. (2003). Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45:935-944.
33. Millan MJ (2002). Descending control of pain. Prog Neurobiol 66:355-474.
34. Murray Cl, Lopez AD (1996). The global burden of disease. Cambridge, Massachusetts: Harvard University Press.
35. Nelson JC, Wohlreich MM, Mallincrodt CH, Detke MJ, Watkin JG, Kennedy JS (2005). Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 13:227-235.
36. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt CH, Lu Y, et al. (2002). Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36:106-132.
37. Ohayon MM (2004). Specific characteristics of the pain/depression association in the general population. J Clin Psychiatry 65 (Suppl 12):5-9.
38. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al. (2005a). A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6:346-356.
39. Raskin J, Pritchett YL, Chappell AS, D'Souza DN, Wong CK (2005b). Duloxetine in the treatment of diabetic neuropathic pain. Results from three clinical trials. Poster presented at the American Psychiatric Association 21-26 May 2005, Atlanta, Georgia, USA.
40. Ren K, Dubner R (2002). Descending modulation in persistent pain: an update. Pain 100:1-6.
41. Retherford RD, Choe MK (1993). Statistical methods for causal analysis. New York: Wiley.
42. Simon GE, Von Korff M, Piccinetti M, Fullerton C, Ormel J (1999). An international study of the relation between somatic symptoms and depression. N Engl J Med 341:1329-1335.
43. Sindrup SH, Jensen TS (1999). Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389-400.
44. Smith GR (1992). The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or pain. Gen Hosp Psychiatry 14:265-272.
45. Stahl SM (2002). Does depression hurt? J Clin Psychiatry 63:273-274.
46. Wohlreich MM, Mallinckrodt CH, Watkin JG, Prakash A (2004). Duloxetine for the treatment of major depressive disorder: safety and efficacy associated with rapid dose escalation (60-120 mg QD). Poster presented at 157th Annual Meeting of the American Psychiatric Association, 1-6 May 2004, New York, New York, USA.
47. Wong DT, Bymaster FP (2002). Dual serotonin and noradrenaline uptake inhibitor class of anti-depressants: potential for greater efficacy or just hype? Prog Drug Res 58:169-222.
48. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushiniki JH, Robertson DW (1993). LY248686, a new inhibitor of serotonin and norepinehrine uptake. Neuropsychopharmacology 8:23-33.